Cristina Cusin is a Psychiatry physician affiliated with Harvard University. OpenAlex indexes 174 publications with 6,651 citations (h-index 44); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Telephone
617-726-2066Registry record last updated 12 Mar 2010.
Clinical trials
- Patient-specific, Effective, and Rational Functional Connectivity Targeting for DBS in OCD
Sponsor: Massachusetts General Hospital
- Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder
Sponsor: Massachusetts General Hospital
- Neurobiological Underpinnings of Placebo Response in Depression
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20255 payments
- Janssen Scientific Affairs, LLCProgram year20252 payments
- LivaNova USA, Inc.Program year20246 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97%Benzodiazepine23%Clonazepam48%Alprazolam29%Lorazepam23%Part D<11 patientsCentral Nervous System Stimulant22.2%Dextroamphetamine-Amphetamine31%Methylphenidate Er29%Methylphenidate Hcl28%Dextroamphetamine-Amphet Er12%Part D<11 patients+ 8 more classes in this area
Cardiovascular
3%Beta blocker3%Propranolol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2012–2019 per NIH RePORTER. The latest:
- Neurobiological Underpinnings of Placebo Response in Depression
Massachusetts General Hospital
FY2019$730,710R01MH102279 - Neurobiological Underpinnings of Placebo Response in Depression
Massachusetts General Hospital
FY2018$755,429R01MH102279 - Neurobiological Underpinnings of Placebo Response in Depression
Massachusetts General Hospital
FY2017$755,429R01MH102279
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation
The Journal of Clinical Psychiatry
2022 - Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors
Frontiers in Psychiatry
2020 - Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Journal of Clinical Psychopharmacology
2020 - Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review
Journal of Affective Disorders
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Sarah Fortune, MD
Harvard University
Rochelle Walensky, MD
Harvard University
Stephen Gomperts, MD
Harvard University
Yakir Levin, MD, PhD
Harvard University
Charles Nemeroff, MD
Dell Medical School
Maurizio Fava, MD
Massachusetts General Hospital
John Krystal, MD
Yale University
Jeffrey Lieberman, MD
Columbia University College of Physicians and Surgeons
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”